These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 9592981

  • 1. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Rossi G, Donisi A, Casari S, Re A, Stellini R, Cadeo G, Carosi G.
    Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
    [Abstract] [Full Text] [Related]

  • 2. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998 Mar; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 4. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
    Costello RT, Zerazhi H, Charbonnier A, de Colella JM, Alzieu C, Poizot-Martin I, Cohen R, Bardou VJ, Xerri L, Olive D, Nezri M, Lepeu G, Gastaut JA.
    Cancer; 2004 Feb 15; 100(4):667-76. PubMed ID: 14770420
    [Abstract] [Full Text] [Related]

  • 5. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
    Hernàndez DE, Hernàndez AE.
    Eur J Cancer Care (Engl); 2006 Dec 15; 15(5):493-6. PubMed ID: 17177909
    [Abstract] [Full Text] [Related]

  • 6. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G.
    Cancer; 1999 Dec 01; 86(11):2391-7. PubMed ID: 10590382
    [Abstract] [Full Text] [Related]

  • 7. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
    Zinzani PL, Martelli M, Tura S, Mandelli F.
    Haematologica; 1993 Dec 01; 78(1):40-3. PubMed ID: 7684011
    [Abstract] [Full Text] [Related]

  • 8. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M, Li L, Qiu M, Yan X, Zhu J, Gou HF.
    Ai Zheng; 2005 Apr 01; 24(4):461-4. PubMed ID: 15820070
    [Abstract] [Full Text] [Related]

  • 9. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P.
    J Clin Oncol; 2003 Aug 15; 21(16):3041-50. PubMed ID: 12915593
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.
    Haematologica; 1998 Sep 15; 83(9):800-11. PubMed ID: 9825577
    [Abstract] [Full Text] [Related]

  • 11. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
    Dotti G, Stella CC, Mangoni L, Cottafavi L, Caramatti C, Almici C, Rizzoli V.
    Haematologica; 1995 Sep 15; 80(2):142-5. PubMed ID: 7543069
    [Abstract] [Full Text] [Related]

  • 12. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 13. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M.
    Biotechnol Annu Rev; 2005 May 01; 11():381-9. PubMed ID: 16216784
    [Abstract] [Full Text] [Related]

  • 14. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM.
    N Engl J Med; 1997 Jun 05; 336(23):1641-8. PubMed ID: 9171066
    [Abstract] [Full Text] [Related]

  • 15. Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
    Okabe M, Maekawa I, Suzuki S, Higuchi M, Morioka M, Nishi K, Itaya T, Ohmura T, Kawamura M, Fuzimoto N.
    Leuk Lymphoma; 1995 Nov 05; 19(5-6):485-91. PubMed ID: 8590851
    [Abstract] [Full Text] [Related]

  • 16. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
    Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, Gómez J, Millá F, Feliu E.
    Haematologica; 1998 Jun 05; 83(6):508-13. PubMed ID: 9676023
    [Abstract] [Full Text] [Related]

  • 17. [Colony-stimulating factors and HIV-related neoplasms].
    Valencia ME, Moreno V, Soriano V, Polo R, Verdejo J, Laguna F, González Lahoz J.
    An Med Interna; 1996 Jul 05; 13(7):317-21. PubMed ID: 8962975
    [Abstract] [Full Text] [Related]

  • 18. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G, Coser P, Congiu AM, Salvagno L, De Souza C, Sertoli MR, Olivieri A, Chisesi T, Rubagotti A, Truini M, Contu A, Porcellini A, Zambaldi G, Nati S, Marino G, Rizzoli V.
    Haematologica; 2000 Feb 05; 85(2):160-6. PubMed ID: 10681723
    [Abstract] [Full Text] [Related]

  • 19. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 05; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 20. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G.
    Bone Marrow Transplant; 1998 May 05; 21(9):873-8. PubMed ID: 9613778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.